FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281750496> ?p ?o ?g. }

• W4281750496 endingPage "e16073" @default.
• W4281750496 startingPage "e16073" @default.
• W4281750496 abstract "e16073 Background: The CCND1 gene is considered an oncogene located on human chromosome 11q13.3, Cyclin D1 protein encoded by the CCND1 gene is the critical gatekeeping protein in charge of regulating the transition. Previous studies have reported that CCND1 amplification associated with a negative response to immune checkpoint inhibitors (ICIs) in pancancers, but the association with clinical and molecular characteristics in esophageal carcinoma (ESCA) have not been researched. Herein, we explore CCND1 amplification profiles in Chinese patients with ESCA. Methods: A total of 59 patients of ESCA with paired tumor-normal samples were collected into the study. All samples were detected by DNA based sequencing with a 1021 gene panel. Results: Firstly, the frequency of CCND1 amplification in Chinese ESCA patients was 32.20% (19/59). Then, all the samples were divided into two groups according to whether CCND1 was amplified or not. In the CCND1 amplification group, the top8 co-mutated genes were TP53, FGF4, FGF3, FGF19, MYC, NOTCH1, CDKN2A, CDKN2B. We calculated the clinical and molecular characteristics between the two groups, the results showed there were no difference in gender, age and TNM stage. Meanwhile, the CCND1 amplification group had more somatic mutations (median 19 vs. 11, P = 0.0003), higher TMB value (median 8.64 vs. 5.76, P = 0.0199) and more TMB-H patients (47.37% vs. 17.50%, P = 0.018). Indicating the CCND1 amplification is associated with TMB-H in ESCA. However, previous studies have reported the negative impact of CCND1 amplification on the efficacy of ICIs in pancancer (including ESCA), these results suggesting the efficacy of ICIs in ESCA may be affected by multiple biomarkers, especially for TMB-H patients should be concerned about the high frequency CCND1 amplification, the patients may have a poorer benefit from immunotherapy. Conclusions: The efficacy of ICIs in ESCA may be affected by multiple biomarkers, especially for TMB-H patients should be concerned about the higher frequency of CCND1 amplification, these patients may have a poorer benefit from immunotherapy.[Table: see text]" @default.
• W4281750496 created "2022-06-13" @default.
• W4281750496 creator A5003506069 @default.
• W4281750496 creator A5008720175 @default.
• W4281750496 creator A5042808523 @default.
• W4281750496 creator A5062147449 @default.
• W4281750496 creator A5068080767 @default.
• W4281750496 creator A5083141635 @default.
• W4281750496 creator A5087153019 @default.
• W4281750496 date "2022-06-01" @default.
• W4281750496 modified "2023-09-23" @default.
• W4281750496 title "The analysis of <i>CCND1</i> amplification in Chinese patients with esophageal carcinoma." @default.
• W4281750496 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e16073" @default.
• W4281750496 hasPublicationYear "2022" @default.
• W4281750496 type Work @default.
• W4281750496 citedByCount "0" @default.
• W4281750496 crossrefType "journal-article" @default.
• W4281750496 hasAuthorship W4281750496A5003506069 @default.
• W4281750496 hasAuthorship W4281750496A5008720175 @default.
• W4281750496 hasAuthorship W4281750496A5042808523 @default.
• W4281750496 hasAuthorship W4281750496A5062147449 @default.
• W4281750496 hasAuthorship W4281750496A5068080767 @default.
• W4281750496 hasAuthorship W4281750496A5083141635 @default.
• W4281750496 hasAuthorship W4281750496A5087153019 @default.
• W4281750496 hasConcept C104317684 @default.
• W4281750496 hasConcept C121608353 @default.
• W4281750496 hasConcept C126322002 @default.
• W4281750496 hasConcept C153911025 @default.
• W4281750496 hasConcept C199835354 @default.
• W4281750496 hasConcept C2780265364 @default.
• W4281750496 hasConcept C2781018059 @default.
• W4281750496 hasConcept C29537977 @default.
• W4281750496 hasConcept C30481170 @default.
• W4281750496 hasConcept C502942594 @default.
• W4281750496 hasConcept C54355233 @default.
• W4281750496 hasConcept C71924100 @default.
• W4281750496 hasConcept C7602840 @default.
• W4281750496 hasConcept C86803240 @default.
• W4281750496 hasConceptScore W4281750496C104317684 @default.
• W4281750496 hasConceptScore W4281750496C121608353 @default.
• W4281750496 hasConceptScore W4281750496C126322002 @default.
• W4281750496 hasConceptScore W4281750496C153911025 @default.
• W4281750496 hasConceptScore W4281750496C199835354 @default.
• W4281750496 hasConceptScore W4281750496C2780265364 @default.
• W4281750496 hasConceptScore W4281750496C2781018059 @default.
• W4281750496 hasConceptScore W4281750496C29537977 @default.
• W4281750496 hasConceptScore W4281750496C30481170 @default.
• W4281750496 hasConceptScore W4281750496C502942594 @default.
• W4281750496 hasConceptScore W4281750496C54355233 @default.
• W4281750496 hasConceptScore W4281750496C71924100 @default.
• W4281750496 hasConceptScore W4281750496C7602840 @default.
• W4281750496 hasConceptScore W4281750496C86803240 @default.
• W4281750496 hasIssue "16_suppl" @default.
• W4281750496 hasLocation W42817504961 @default.
• W4281750496 hasOpenAccess W4281750496 @default.
• W4281750496 hasPrimaryLocation W42817504961 @default.
• W4281750496 hasRelatedWork W1991172032 @default.
• W4281750496 hasRelatedWork W2071072996 @default.
• W4281750496 hasRelatedWork W2073975117 @default.
• W4281750496 hasRelatedWork W2165508746 @default.
• W4281750496 hasRelatedWork W2403342586 @default.
• W4281750496 hasRelatedWork W2557243074 @default.
• W4281750496 hasRelatedWork W2586385055 @default.
• W4281750496 hasRelatedWork W2766561475 @default.
• W4281750496 hasRelatedWork W2797352271 @default.
• W4281750496 hasRelatedWork W2904602238 @default.
• W4281750496 hasVolume "40" @default.
• W4281750496 isParatext "false" @default.
• W4281750496 isRetracted "false" @default.
• W4281750496 workType "article" @default.